...Oscar L. Lopez; Diana Claassen The presence of cerebral amyloid angiopathy (CAA) in capillaries and arterioles of the cerebral and cerebellar cortex of Alzheimer's disease (AD) patients may provide an opportunity to study the clinical significance of these vascular changes in AD. We reviewed...

... content of cobalamin in the control group is in line with but somewhat lower than what has been reported in previous studies [15, 2224, 34, 43], This might be an effect of higher age in our Cobalamin in Alzheimer's Disease 329 Fig. 2. Remcthylation of ho­ mocysteine to methionine is de­ pendent...

... in Alzheimer's disease and karyotypically normal Down syndrome. Science 1987:235:1390-1392. 86 Graham DI. Adams JH, Gennarelli TA: Pathology of brain dam­ age in head injury; in Cooper PR (cd): Head Injury. Baltimore. Williams & Wilkins. 1987. pp 72-88. 87 Kmieciak KK. Felinska W. Stachura Z. et al...

... inhibitor Depression Parkinson's disease Alzheimer's disease © 1990 S. Karger AG, Basel 1990 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic...

...J.P. Brion; M.E. Cheetham; A.M. Couck; J. Flament-Durand; D.P. Hanger; B.H. Anderton A cDNA encoding epitopes present in paired helical filaments (PHF) in Alzheimer's disease has been characterized by DNA sequencing and by immunochemical analysis of the encoded recombinant protein fragment...

... are living today. In preparation for a study of Alzheimer's disease (AD) in this Registry, we investigated 829 members of pairs living in North and South Carolina, Virginia, in the District of Columbia, and Maryland. A brief telephone interview for cognitive symptoms was administered to 678 (91.4%) of 742...

... -deprenyl. Other potential mechanisms are discussed. 17 07 1990 26 5 2010 Deprenyl Dopamine Monoamine oxidase B inhibitor Depression Parkinson's disease Alzheimer's disease iiw ^uw tL sm B w rfaM ^IW W -'M a s »i Potential Applications for MAO-B Inhibitors 335 It is thought...

... of caregiver's feelings of burden on their perception of the patients' functional status and to establish the predictors of feelings of burden. Twenty-five probable Alzheimer disease patients (NINCDS-ADRDA criteria) were assessed on cognitive measures and functional status (DAFS). The caregiver's index of burden...

...Samuel A. Scott The current study examined changes in the dendritic arbor of basolateral amygdaloid neurons in Alzheimer's disease (AD). Quantitative analysis of Golgi Kopsch-impregnated tissue samples revealed a significant reduction in the total dendritic length per neuron in AD. Terminal...

...R.A. Armstrong; D. Myers; C.U.M. Smith The density of diffuse, primitive, classic and compact Β/A4 deposits was estimated in the cortex and hippocampus in Alzheimer's disease (AD) cases with and without pronounced congophilic angiopathy (CA). The total density of Β/A4 deposits in a given brain...

...Janice Robertson; Thérêse L.F Loviny; Michel Goedert; Ross Jakes; Kenneth J. Murray; Brian H. Anderton; Diane P. Hanger Alzheimer's disease paired helical filaments contain abnormally phosphorylated tau (PHF-tau) which has reduced electrophoretic mobility on sodium dodecyl sulphate polyacrylamide...

.... Cerebrospinal fluid Neuropeptide Y Alzheimer's disease Frontotemporal degeneration of non-Alzheimer type Dementia 1990;1:262-266 © 1990S. Karger AG, Basel 1013-7424/90/0015-0262S2.75/0 Cerebrospinal Fluid Neuropeptide Y-Like Immunoreactive Levels in Dementia of Alzheimer Type and Dementia...

... Attention Cognition Cognitive test battery MMSE Aging Alzheimer's disease Parkinson's disease Factor analysis CANTAB Review Dementia 1994;5:266-281 T W. Robbinsa M. Jamesb A M . Owena B.J. Sahakian* L. M dnnesc P. Rabbind a Department of Experimental Psychology, University of Cambridge, b...

...Linda Bierer; Paul S. Aisen; Michael Davidson; Theresa M. Ryan; James Schmeidler; Kenneth L. Davis To assess the feasibility of one approach to combined cholinergic/noradrenergic treatment in Alzheimer's disease, ten patients were enrolled in a 2-week placebo-controlled study of oral physostigmine...

...C.R. Harrington; R.H. Perry; E.K. Perry; J. Hurt; I.G. McKeith; M. Roth; C.M. Wischik We have used biochemical assays to examine cingulate and occipital cortices from age-matched cases of Alzheimer's disease (AD; n = 12), senile dementia of the Lewy body type (SDLT; n = 13), Parkinson's disease (PD...

...R.A. Armstrong The density of senile plaques (SP) and neurofibrillary tangles (NFT) was estimated at post-mortem in areas B17 and B18 of the visual cortex in 18 Alzheimer's disease (AD) cases which varied in disease onset and duration. The density of SP in B17 and NFT in B17 and B18 declined...

...C.R. Harrington; R.H. Perry; E.K. Perry; J. Hurt; I.G. McKeith; M. Roth; C.M. Wischik We have used biochemical assays to examine cingulate and occipital cortices from age-matched cases of Alzheimer's disease (AD; n = 12), senile dementia of the Lewy body type (SDLT; n = 13), Parkinson's disease (PD...

...Lutz M. Drach; Jürgen Bohl; Hans-H. Goebel Lipofuscin, the age pigment, is of interest in Alzheimer's disease because of its property to accumulate in neurons and because of the hypothesis that Alzheimer's dementia is a kind of premature ageing. The amount of intraneuronal lipofuscin...

...Jan Balldin; Kaj Blennow; Görel Bråne; C.G. Gottfries; Ingvar Karlsson; Björn Regland; Anders Wallin In 40 patients with Alzheimer's disease (AD, <65 years), 56 patients with senile dementia of the Alzheimer type (SDAT, ≥65 years) and 45 patients with vascular dementia (VAD), basal cortisol...

... disease, but its prevalence in non-Alzheimer dementias in Caucasian populations is unknown. We found that the frequency of the apoE Ε4 allele was 0.45 in 93 Alzheimer's disease patients, 0.46 in 23 vascular dementia patients, 0.31 in 13 dementia of the frontal type patients, and 0.18 in 51 elderly...